Blood plasma, another component of ECF, carries biomarkers that can indicate the presence of cancer. Changes in the levels of circulating tumor cells, DNA, RNA, proteins, and metabolites in plasma can serve as potential diagnostic and prognostic markers for cancer. Advances in liquid biopsy technologies are making it increasingly feasible to detect these alterations, offering a minimally invasive method for cancer detection and monitoring.
